Subscribe To
Veracyte, inc. (vcyt) q1 2023 earnings call transcript
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participa...
May 4, 2023, 10:43 pm
Incyte (incy) q1 earnings miss estimates, revenues up y/y
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibl...
May 2, 2023, 4:51 pm
Incyte (incy) q1 earnings and revenues miss estimates
Incyte (INCY) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate...
May 2, 2023, 9:54 am
Humacyte to present at the h.c. wainwright bioconnect investor conference at nasdaq
DURHAM, N.C., April 28, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biote...
April 28, 2023, 12:00 pm
Oncocyte to announce first quarter 2023 financial results
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision dia...
April 27, 2023, 4:59 pm
cytek biosciences, inc. (ctkb) soars 13.4%: is further upside left in the stock?
cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading vo...
April 27, 2023, 4:34 am
Will jakafi sales drive a beat for incyte (incy) q1 earnings?
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incr...
April 26, 2023, 12:11 pm
Vaxcyte announces closing of $575 million public offering including full exercise of underwriters’ option to purchase additional shares
SAN CARLOS, Calif., April 21, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 21, 2023, 9:25 pm
Incyte (incy) opzelura gets ec nod for non-segmental vitiligo
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non...
April 21, 2023, 2:26 pm
Vaxcyte announces pricing of $500 million public offering
SAN CARLOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 19, 2023, 4:26 am
Vaxcyte (pcvx) up on pneumococcal conjugate vaccine data
Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjug...
April 18, 2023, 2:28 pm
Still 50% upside to go, wall street is getting vaxcyte right
When SVB Securities analyst David Risinger reiterated his bullish opinion on Vaxcyte, Inc. (NASDAQ: PCV...
April 18, 2023, 8:36 am
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage ...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm